Evidence map›Paper›PMID 38018890›Full record

ReviewThe British journal of nutrition2023

Ergothioneine: an underrecognised dietary micronutrient required for healthy ageing?

Xiaoying Tian, James L Thorne, J Bernadette Moore

Registry-linked trialOpen access · hybridAbstract readReview
In one paragraph

Review in The British journal of nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07750002 (A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of NVTIA® Ergothioneine Supplementation on Healthy Aging Biomarkers and Skin Health in Healthy Adults), which is not on this map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
16.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07750002 narecruitingnot on this mapstarted 2026, after this paper: background citation

A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Effects of NVTIA® Ergothioneine Supplementation on Healthy Aging Biomarkers and Skin Health in Healthy Adults

TypeinterventionalSponsorEUROPEAN LIFE SCIENCE RESEARCH ASSOCIATIONRan2026 to 2027Enrolled50ConditionsHealthy Aging, Skin Aging, Oxidative StressArmsNVTIA® Ergothioneine, Placebo
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Development of HybridFoods (Basel, Switzerland) · 2025
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Xiaoying TianSchool of Food Science & Nutrition, University of Leeds, Leeds, LS2 9JT, UK.ORCID 0000-0003-4641-4332
James L ThorneSchool of Food Science & Nutrition, University of Leeds, Leeds, LS2 9JT, UK.
J Bernadette MooreSchool of Food Science & Nutrition, University of Leeds, Leeds, LS2 9JT, UK.ORCID 0000-0003-4750-1550
University of Leeds · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ergothioneine is a naturally occurring amino acid and thiol antioxidant found in high amounts in mushrooms and fermented foods. Humans and animals acquire ergothioneine from the diet through the pH-dependent activity of a membrane transporter, the large solute carrier 22A member 4 (SLC22A4), expressed on the apical membrane of the small intestine. The SLC22A4 transporter also functions in the renal reabsorption of ergothioneine in the kidney, with avid absorption and retention of ergothioneine from the diet observed in both animals and humans. Ergothioneine is capable of scavenging a diverse range of reactive oxygen and nitrogen species, has metal chelation properties, and is predicted to directly regulate nuclear factor erythroid 2-related factor 2 (Nrf2) activity. Although not lethal, the genetic knockout of the SLC22A4 gene in multiple organisms increases susceptibility to oxidative stress, damage and inflammation; in agreement with a large body of preclinical data suggesting the physiological function of ergothioneine is as a cellular antioxidant and cytoprotectant agent. In humans, blood levels of ergothioneine decline after the age of 60 years, and lower levels of ergothioneine are associated with more rapid cognitive decline. Conversely, high plasma ergothioneine levels have been associated with significantly reduced cardiovascular mortality and overall mortality risks. In this horizon’s manuscript, we review evidence suggesting critical roles for dietary ergothioneine in healthy ageing and the prevention of cardiometabolic disease. We comment on some of the outstanding research questions in the field and consider the question of whether or not ergothioneine should be considered a conditionally essential micronutrient.

Indexed as

ErgothioneineHealthy AgingSymportersAnimalsAntioxidantsDietHumansMiddle AgedOrganic Cation Transport ProteinsAntioxidantsErgothioneineOrganic Cation Transport ProteinsSymportersCardiometabolic diseaseCVDErgothioneineNon-alcoholic fatty liver diseaseType 2 diabetes

Identifiers

PMID38018890
PMCPMC9816654
OpenAlexW4313570263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.